<DOC>
	<DOCNO>NCT01751295</DOCNO>
	<brief_summary>The purpose study evaluate effect statin coronary microcirculation dysfunction measure percutaneous coronary intervention .</brief_summary>
	<brief_title>Statin Post-interventional Coronary Microcirculation Dysfunction</brief_title>
	<detailed_description>Development peri-procedural myocardial infarction follow percutaneous coronary intervention ( PCI ) uncommon affect long-term prognosis . Clinical study show pre-treatment atorvastatin reduce peri-procedural myocardial infarction patient stable angina . The mechanism peri-procedural myocardial infarction presume microvascular embolization . However direct causal relationship statin pretreatment prevention microvascular dysfunction investigate yet . In study , recruit symptomatic angina patient clinical indication coronary angiography . At time enrollment , patient randomly assign pre-treatment group ( atorvastatin 80 mg/d 4 day ) control group . Percutaneous coronary intervention ( PCI ) perfomed base result diagnostic coronary angiography decision attend physician . When PCI perform , fractional flow reserve ( FFR ) index microvascular resistance ( IMR ) measure procedure . Periprocedural myocardial infarction define post-PCI cardiac biomarker . All patient follow adverse cardiac event 1 year .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>A . Finished inform consent B . Stable angina clinical indication coronary angiography C. Age ≥ 21 year ≤ 80 year A.Without inform consent B.PCI target lesion adequate indicate FFR/IMR study C.Prior myocardial infarction interventional procedure PCI target vessel D.Myocardial infarction within 30 day E.Usage statin , current within 1 month F.Prior bypass surgery G.Impaired renal function ( Creatinine &gt; 2.0 mg/dL ) H.Impaired left ventricular function ( ejection fraction &lt; 40 % ) I.Active hepatitis abnormal hepatic transaminase level ( &gt; 3 ULN ) J.Contraindication longterm antiplatelet agent statin K.Planning potential pregnancy L.Neoplastic disease without evidence treatment completion M.Impaired general condition</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>